DOI QR코드

DOI QR Code

Efficacy and safety of endoscopic submucosal dissection for colorectal dysplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis

  • Talia F. Malik (Department of Internal Medicine, Chicago Medical School at Rosalind Franklin University of Medicine and Science) ;
  • Vaishnavi Sabesan (Department of Gastroenterology and Hepatology, University of Utah School of Medicine) ;
  • Babu P. Mohan (Department of Gastroenterology and Hepatology, Orlando Gastroenterology PA) ;
  • Asad Ur Rahman (Department of Gastroenterology and Hepatology, Cleveland Clinic Florida) ;
  • Mohamed O. Othman (Gastroenterology and Hepatology Section, Baylor College of Medicine) ;
  • Peter V. Draganov (Department of Gastroenterology, Hepatology, and Nutrition, University of Florida) ;
  • Gursimran S. Kochhar (Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network)
  • Received : 2023.08.11
  • Accepted : 2023.09.27
  • Published : 2024.05.30

Abstract

Background/Aims: In this meta-analysis, we studied the safety and efficacy of endoscopic submucosal dissection (ESD) for colorectal dysplasia in patients with inflammatory bowel disease (IBD). Methods: Multiple databases were searched, and studies were retrieved based on pre-specified criteria until October 2022. The outcomes assessed were resection rates, procedural complications, local recurrence, metachronous tumors, and the need for surgery after ESD in IBD. Standard meta-analysis methods were followed using the random-effects model, and I2% was used to assess heterogeneity. Results: Twelve studies comprising 291 dysplastic lesions in 274 patients were included with a median follow-up of 25 months. The pooled en-bloc resection, R0 resection, and curative resection rates were 92.5% (95% confidence interval [CI], 87.9%-95.4%; I2=0%), 81.5% (95% CI, 72.5%-88%; I2=43%), and 48.9% (95% CI, 32.1%-65.9%; I2=87%), respectively. The local recurrence rate was 3.9% (95% CI, 2%-7.5%; I2=0%). The pooled rates of bleeding and perforation were 7.7% (95% CI, 4.5%-13%; I2=10%) and 5.3% (95% CI, 3.1%-8.9%; I2=0%), respectively. The rates of metachronous recurrence and additional surgery following ESD were 10% (95% CI, 5.2%-18.2%; I2=55%) and 13% (95% CI, 8.5%-19.3%; I2=54%), respectively. Conclusions: ESD is safe and effective for the resection of dysplastic lesions in IBD with an excellent pooled rate of en-bloc and R0 resection.

Keywords

References

  1. Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375-381.  https://doi.org/10.1053/j.gastro.2012.04.016
  2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535.  https://doi.org/10.1136/gut.48.4.526
  3. Choi CH, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol 2015;110:1022-1034.  https://doi.org/10.1038/ajg.2015.65
  4. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:829-854.  https://doi.org/10.1055/s-0034-1392882
  5. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology 2015;148:639-651.  https://doi.org/10.1053/j.gastro.2015.01.031
  6. American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015;81:1101-1121.  https://doi.org/10.1016/j.gie.2014.10.030
  7. Rutter MD, Riddell RH. Colorectal dysplasia in inflammatory bowel disease: a clinicopathologic perspective. Clin Gastroenterol Hepatol 2014;12:359-367.  https://doi.org/10.1016/j.cgh.2013.05.033
  8. Draganov PV, Wang AY, Othman MO, et al. AGA institute clinical practice update: endoscopic submucosal dissection in the United States. Clin Gastroenterol Hepatol 2019;17:16-25.  https://doi.org/10.1016/j.cgh.2018.07.041
  9. Uraoka T, Parra-Blanco A, Yahagi N. Colorectal endoscopic submucosal dissection in Japan and Western countries. Dig Endosc 2012;24 Suppl 1:80-83.  https://doi.org/10.1111/j.1443-1661.2012.01279.x
  10. Hurlstone DP, Sanders DS, Atkinson R, et al. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut 2007;56:838-846.  https://doi.org/10.1136/gut.2006.106294
  11. Wang J, Zhang XH, Ge J, et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: a meta-analysis. World J Gastroenterol 2014;20:8282-8287.  https://doi.org/10.3748/wjg.v20.i25.8282
  12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021;10:89. 
  13. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.  https://doi.org/10.1001/jama.283.15.2008
  14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-605.  https://doi.org/10.1007/s10654-010-9491-z
  15. Iacopini F, Saito Y, Yamada M, et al. Curative endoscopic submucosal dissection of large nonpolypoid superficial neoplasms in ulcerative colitis (with videos). Gastrointest Endosc 2015;82:734-738.  https://doi.org/10.1016/j.gie.2015.02.052
  16. Kasuga K, Yamada M, Shida D, et al. Treatment outcomes of endoscopic submucosal dissection and surgery for colorectal neoplasms in patients with ulcerative colitis. United European Gastroenterol J 2021;9:964-972.  https://doi.org/10.1002/ueg2.12118
  17. Kochhar G, Steele S, Sanaka M, et al. Endoscopic submucosal dissection for flat colonic polyps in patients with inflammatory bowel disease: a single-center experience. Inflamm Bowel Dis 2018;24:e14-e15.  https://doi.org/10.1093/ibd/izy101
  18. Kinoshita S, Nishizawa T, Yahagi N, et al. Endoscopic submucosal dissection in patients with ulcerative colitis. Digestion 2019;99:27-32.  https://doi.org/10.1159/000494409
  19. Lightner AL, Vaidya P, Allende D, et al. Endoscopic submucosal dissection is safe and feasible, allowing for ongoing surveillance and organ preservation in patients with inflammatory bowel disease. Colorectal Dis 2021;23:2100-2107.  https://doi.org/10.1111/codi.15746
  20. Matsumoto K, Oka S, Tanaka S, et al. Long-term outcomes after endoscopic submucosal dissection for ulcerative colitis-associated dysplasia. Digestion 2021;102:205-215.  https://doi.org/10.1159/000503341
  21. Manta R, Zullo A, Telesca DA, et al. Endoscopic submucosal dissection for visible dysplasia treatment in ulcerative colitis patients: cases series and systematic review of literature. J Crohns Colitis 2021;15:165-168.  https://doi.org/10.1093/ecco-jcc/jjaa158
  22. Matsui A, Hoteya S, Hayasaka J, et al. Real-world experience of endoscopic submucosal dissection for ulcerative colitis-associated neoplasia. Inflamm Intest Dis 2021;6:70-77.  https://doi.org/10.1159/000512292
  23. Ngamruengphong S, Aihara H, Friedland S, et al. Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study. Endosc Int Open 2022;10:E354-E360.  https://doi.org/10.1055/a-1783-8756
  24. Nishio M, Hirasawa K, Ozeki Y, et al. An endoscopic treatment strategy for superficial tumors in patients with ulcerative colitis. J Gastroenterol Hepatol 2021;36:498-506.  https://doi.org/10.1111/jgh.15207
  25. Suzuki N, Toyonaga T, East JE. Endoscopic submucosal dissection of colitis-related dysplasia. Endoscopy 2017;49:1237-1242.  https://doi.org/10.1055/s-0043-114410
  26. Yang DH, Kim J, Song EM, et al. Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection. J Gastroenterol Hepatol 2019;34:1581-1589.  https://doi.org/10.1111/jgh.14623
  27. Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 
  28. Alkandari A, Thayalasekaran S, Bhandari M, et al. Endoscopic resections in inflammatory bowel disease: a multicentre European outcomes study. J Crohns Colitis 2019;13:1394-1400.  https://doi.org/10.1093/ecco-jcc/jjz075
  29. Yadav S, Loftus EV Jr, Harmsen WS, et al. Outcome of endoscopic resection of colonic polyps larger than 10mm in patients with inflammatory bowel disease. Endosc Int Open 2019;7:E994-E1001.  https://doi.org/10.1055/a-0953-2021
  30. Yu JX, Lin JL, Oliver M, et al. Trends in EMR for nonmalignant colorectal polyps in the United States. Gastrointest Endosc 2020;91:124-131.  https://doi.org/10.1016/j.gie.2019.08.004
  31. Akintoye E, Kumar N, Aihara H, et al. Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis. Endosc Int Open 2016;4:E1030-E1044.  https://doi.org/10.1055/s-0042-114774
  32. Patel N, Patel K, Ashrafian H, et al. Colorectal endoscopic submucosal dissection: systematic review of mid-term clinical outcomes. Dig Endosc 2016;28:405-416.  https://doi.org/10.1111/den.12597
  33. Mohapatra S, Sankaramangalam K, Lopimpisuth C, et al. Advanced endoscopic resection for colorectal dysplasia in inflammatory bowel disease: a meta-analysis. Endosc Int Open 2022;10:E593-E601.  https://doi.org/10.1055/a-1784-7063
  34. Chen W, Zhang YL, Zhao Y, et al. Endoscopic resection for non-polypoid dysplasia in inflammatory bowel disease: a systematic review and meta-analysis. Surg Endosc 2021;35:1534-1543. https://doi.org/10.1007/s00464-020-08225-9